Genelux Corporation (GNLX)

US — Healthcare Sector
Peers: CMRA  DYAI  CING  MNPR  TERN  DAWN  ABOS  AMLX  MLTX  GLUE  NAMS  IVA  CGEM  CMPX  LRMR  IMRX  CNTA  CELC  IKNA 

Automate Your Wheel Strategy on GNLX

With Tiblio's Option Bot, you can configure your own wheel strategy including GNLX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol GNLX
  • Rev/Share 0.0129
  • Book/Share 0.8545
  • PB 2.867
  • Debt/Equity 0.0599
  • CurrentRatio 4.6749
  • ROIC -0.9925

 

  • MktCap 92450667.0
  • FreeCF/Share -0.6497
  • PFCF -4.0745
  • PE -2.8996
  • Debt/Assets 0.0458
  • DivYield 0
  • ROE -0.9304

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 2
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation GNLX ROTH MKM -- Buy -- $10 Aug. 28, 2024

News

Genelux Corporation (GNLX) Upgraded to Buy: Here's What You Should Know
GNLX
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Positive

Genelux Corporation (GNLX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Read More
image for news Genelux Corporation (GNLX) Upgraded to Buy: Here's What You Should Know
Down -29.7% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround
GNLX
Published: March 28, 2025 by: Zacks Investment Research
Sentiment: Positive

Genelux Corporation (GNLX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Read More
image for news Down -29.7% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround
Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock
GNLX
Published: March 25, 2025 by: GlobeNewsWire
Sentiment: Neutral

WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten offering of 3,000,000 shares of its common stock at an offering price of $3.50 per share. The gross proceeds to Genelux from the offering are expected to be $10.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Genelux.

Read More
image for news Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock

About Genelux Corporation (GNLX)

  • IPO Date 2023-01-26
  • Website https://www.genelux.com
  • Industry Biotechnology
  • CEO Mr. Thomas Zindrick J.D.
  • Employees 24
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.